Search - tctmd.com

Displaying 21 - 40 of 410

Sort: Relevancy | Date

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

Todd Neale

November 08, 2025

News Daily News

ACC: It’s Time for Clinicians to Address Inflammation in CVD

Caitlin E. Cox

October 03, 2025

News Daily News

Evolocumab Wins for Primary Prevention in VESALIUS-CV

L.A. McKeown

October 03, 2025

News Opinion CV Team Dispatch

September 2025 Dispatch for the CV Team

L.A. McKeown

September 30, 2025

News Daily News

CVD Still the Leading Cause of Death and Disease Globally

Michael O'Riordan

September 24, 2025

News Daily News

Good LDL Control When PCSK9 Inhibitors Given In-Hospital After Interventions

L.A. McKeown

September 22, 2025

News Conference News ESC 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Michael O'Riordan

September 10, 2025

News Conference News ESC 2025

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

Michael O'Riordan

September 04, 2025

News Conference News ESC 2025

Olezarsen Brings Moderately High Triglycerides Under Control: Essence-TIMI 73b

Caitlin E. Cox

August 31, 2025

News Conference News ESC 2025

High hs-CRP Linked to More CVD Events in Women Lacking Traditional Risk Factors

Caitlin E. Cox

August 29, 2025

News Daily News

Body Fat Distribution Influences Cardiovascular Age

Todd Neale

August 22, 2025

News Daily News

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Michael O'Riordan

August 06, 2025

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

News Conference News SCCT 2025

AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry

Yael L. Maxwell

July 21, 2025

News Daily News

GLP-1s May Stave Off Dementia, EHR-Based Study Shows

Caitlin E. Cox

July 21, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Conference News European Congress on Obesity 2025

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

Michael O'Riordan

May 14, 2025

News Conference News EAS 2025

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Yael L. Maxwell

May 08, 2025

News Daily News

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Michael O'Riordan

May 07, 2025

Advertisement

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

ACC: It’s Time for Clinicians to Address Inflammation in CVD

Evolocumab Wins for Primary Prevention in VESALIUS-CV

September 2025 Dispatch for the CV Team

CVD Still the Leading Cause of Death and Disease Globally

Good LDL Control When PCSK9 Inhibitors Given In-Hospital After Interventions

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

Olezarsen Brings Moderately High Triglycerides Under Control: Essence-TIMI 73b

High hs-CRP Linked to More CVD Events in Women Lacking Traditional Risk Factors

Body Fat Distribution Influences Cardiovascular Age

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry

GLP-1s May Stave Off Dementia, EHR-Based Study Shows

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content